The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol. 2015.
PMID: 24948369
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 0 |
Search Results
5 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol. 2015 Feb;135(2):337-42. doi: 10.1016/j.jaci.2014.04.036. Epub 2014 Jun 17.
J Allergy Clin Immunol. 2015.
PMID: 24948369
Review.
In patients given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers, and the factors that initiate the clinical symptoms of wheal, flare, and itch arise from within the patient. ...Administration of om …
In patients given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers, an …
Chronic spontaneous urticaria: new evidences on the role of autoimmunity.
Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):438-445. doi: 10.1097/ACI.0000000000000927. Epub 2023 Jul 6.
Curr Opin Allergy Clin Immunol. 2023.
PMID: 37459281
Review.
PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the recent advancements and relevance of the autoimmune theories in chronic spontaneous urticaria (CSU). RECENT FINDINGS: Two primary types of autoimmunity, Type I and Type IIb, have e …
PURPOSE OF REVIEW: The purpose of this review is to provide an overview of the recent advancements and relevance of the autoimmune theories …
Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Cell Immunol. 2020 Dec;358:104215. doi: 10.1016/j.cellimm.2020.104215. Epub 2020 Sep 12.
Cell Immunol. 2020.
PMID: 33137647
Review.
Omalizumab is an anti-IgE humanized monoclonal antibody approved for the treatment of severe asthma and chronic spontaneous urticaria. ...However, the biological events occurring on basophils during the therapy with omalizumab are multiple and c …
Omalizumab is an anti-IgE humanized monoclonal antibody approved for the treatment of severe asthma and chronic spontaneous …
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Allergy. 2017 Apr;72(4):519-533. doi: 10.1111/all.13083. Epub 2017 Jan 4.
Allergy. 2017.
PMID: 27861988
Free PMC article.
Review.
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H(1) -antihistamine treatment. ...However, no …
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chron …
Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.
Pediatr Allergy Immunol. 2016 Aug;27(5):446-51. doi: 10.1111/pai.12584. Epub 2016 May 18.
Pediatr Allergy Immunol. 2016.
PMID: 27090058
Review.
Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcepsilonRI on mast cells and basophils has been approved for severe persistent all …
Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, wh …
Cite